Document Detail

Effects of lifestyle changes and metformin on salt sensitivity and nitric oxide metabolism in obese salt-sensitive Hispanics.
MedLine Citation:
PMID:  17460713     Owner:  NLM     Status:  MEDLINE    
Salt sensitivity is associated with obesity, and increased cardiovascular morbidity and mortality. We investigated whether treatment of obesity and its associated metabolic abnormalities corrects salt sensitivity and restores impaired nitric oxide (NO) metabolism characteristic of salt sensitivity. Twenty, otherwise, healthy obese salt-sensitive subjects completed a 12-month program of caloric restriction, aerobic exercise and metformin. Two salt sensitivity tests were performed, that is at baseline and end of program. Lifestyle-metformin treatment decreased weight (9.8+/-0.3 kg), body mass index (3.9+/-0.2 kg/m(2)), waist (11.5+/-0.5 cm), systolic blood pressure (SBP) (8.6+/-0.4 mm Hg), diastolic blood pressure (DBP) (5.5+/-0.4 mm Hg), triglyceride (40+/-5 mg/dl), fasting (8.3+/-1 microIU/ml) and post-load (20+/-4 microIU/ml) insulin levels, and salt sensitivity. Going from a high-sodium ( approximately 300 mmol) to a low-sodium diet ( approximately 30 mmol of sodium/day) lowered SBP/DBP by 14.7+/-1.7/7.4+/-0.9 mm Hg at baseline and by 8.6+/-1.9/3.2+/-1.2 mm Hg after treatment (P<0.001). More importantly, blood pressure (BP) sensitivity to customary levels of dietary salt ( approximately 150 mmol of sodium/day) was abolished by the lifestyle-metformin treatment. Differences in SBP/DBP between usual and low salt averaged 11+/-1/8+/-1 mm Hg before treatment, and 3+/-1/1+/-0.5 mm Hg after treatment (P<0.001). At baseline, NO-metabolite excretion was inhibited during high salt; this impairment was corrected by the lifestyle-metformin treatment. In conclusion, acquired correctable factors play an important role in the pathogenesis of salt sensitivity associated with obesity. Correction of salt sensitivity may account for the BP lowering induced by weight reduction. Restoration of the inability to increase or sustain NO production in response to high salt could account for the correction of salt sensitivity induced by the lifestyle-metformin treatment.
I S Hoffmann; A B Alfieri; L X Cubeddu
Related Documents :
7498993 - Cardiovascular effects of a specific nonpeptide antagonist of substance p (nk-1) recept...
15117913 - Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-pro...
15082033 - Effect of aerosolized milrinone during drug-induced pulmonary hypertension in lambs.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2007-04-26
Journal Detail:
Title:  Journal of human hypertension     Volume:  21     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  2007 Jul 
Date Detail:
Created Date:  2007-06-21     Completed Date:  2007-08-17     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  571-8     Citation Subset:  IM    
School of Pharmacy, Clinical Pharmacology Unit, Center for the Detection and Treatment of Silent Risk Factors for Cardiovascular and Metabolic Diseases, Central University of Venezuela, Caracas, Venezula.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Blood Pressure / physiology
Caloric Restriction
Exercise / physiology
Hypoglycemic Agents / therapeutic use*
Metformin / therapeutic use*
Middle Aged
Nitric Oxide / metabolism*
Obesity / metabolism,  physiopathology,  therapy*
Sodium Chloride, Dietary / metabolism*
Reg. No./Substance:
0/Hypoglycemic Agents; 0/Sodium Chloride, Dietary; 10102-43-9/Nitric Oxide; 657-24-9/Metformin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The interarm blood pressure difference as predictor of cardiovascular events in patients with hypert...
Next Document:  Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring i...